ProMIS Neurosciences (PMN) Registration Filing summary

Company overview and business model

• Focuses on developing antibody therapies and therapeutic vaccines for neurodegenerative and protein-misfolding diseases, targeting Alzheimer's, multiple system atrophy, and ALS.

• Utilizes a proprietary technology platform combining protein biology, physics, and supercomputing to selectively target toxic misfolded proteins.

• Lead product candidate PMN310 targets toxic amyloid-beta oligomers in Alzheimer's; Phase 1a topline data showed good tolerability, with Phase 1b to start in H2 2024.

• Pipeline includes PMN267 for ALS and PMN442 for synucleinopathies, both showing selective binding in preclinical studies.

• Operations have been funded primarily through public and private placements of equity and convertible debt.

Financial performance and metrics

• Raised approximately $30.3 million in gross proceeds from a private placement in July 2024, selling common share units and pre-funded units.

• Common shares are listed on Nasdaq under the symbol “PMN”; closing price was $1.26 on August 26, 2024.

Use of proceeds and capital allocation

• Proceeds from warrant exercises, if any, will be used to advance clinical development of PMN310, as well as for working capital and general corporate expenses.

• No assurance that any warrants will be exercised; company will not receive proceeds from resale of shares by selling securityholders.